<?xml version='1.0' encoding='utf-8'?>
<document id="25152400"><sentence text="Molecular mechanism of an adverse drug-drug interaction of allopurinol and furosemide in gout treatment."><entity charOffset="59-70" id="DDI-PubMed.25152400.s1.e0" text="allopurinol" /><entity charOffset="75-85" id="DDI-PubMed.25152400.s1.e1" text="furosemide" /><pair ddi="false" e1="DDI-PubMed.25152400.s1.e0" e2="DDI-PubMed.25152400.s1.e0" /><pair ddi="false" e1="DDI-PubMed.25152400.s1.e0" e2="DDI-PubMed.25152400.s1.e1" /></sentence><sentence text="Gout patients receiving a combination of allopurinol and furosemide require higher allopurinol doses to achieve the target serum urate (SU) of &lt;6 mg/dl (Stamp et al"><entity charOffset="41-52" id="DDI-PubMed.25152400.s2.e0" text="allopurinol" /><entity charOffset="57-67" id="DDI-PubMed.25152400.s2.e1" text="furosemide" /><entity charOffset="83-94" id="DDI-PubMed.25152400.s2.e2" text="allopurinol" /><entity charOffset="136-138" id="DDI-PubMed.25152400.s2.e3" text="SU" /><pair ddi="false" e1="DDI-PubMed.25152400.s2.e0" e2="DDI-PubMed.25152400.s2.e0" /><pair ddi="false" e1="DDI-PubMed.25152400.s2.e0" e2="DDI-PubMed.25152400.s2.e1" /><pair ddi="false" e1="DDI-PubMed.25152400.s2.e0" e2="DDI-PubMed.25152400.s2.e2" /><pair ddi="false" e1="DDI-PubMed.25152400.s2.e0" e2="DDI-PubMed.25152400.s2.e3" /><pair ddi="false" e1="DDI-PubMed.25152400.s2.e1" e2="DDI-PubMed.25152400.s2.e1" /><pair ddi="false" e1="DDI-PubMed.25152400.s2.e1" e2="DDI-PubMed.25152400.s2.e2" /><pair ddi="false" e1="DDI-PubMed.25152400.s2.e1" e2="DDI-PubMed.25152400.s2.e3" /><pair ddi="false" e1="DDI-PubMed.25152400.s2.e2" e2="DDI-PubMed.25152400.s2.e2" /><pair ddi="false" e1="DDI-PubMed.25152400.s2.e2" e2="DDI-PubMed.25152400.s2.e3" /></sentence><sentence text=", 2012) [1]" /><sentence text=" Our study aimed to identify the molecular basis for this observation" /><sentence text=" We used a fluorimetric assay to determine the impact of furosemide and oxypurinol (the active metabolite of allopurinol) on xanthine oxidase (XO) activity"><entity charOffset="57-67" id="DDI-PubMed.25152400.s5.e0" text="furosemide" /><entity charOffset="72-82" id="DDI-PubMed.25152400.s5.e1" text="oxypurinol" /><entity charOffset="109-120" id="DDI-PubMed.25152400.s5.e2" text="allopurinol" /><entity charOffset="125-133" id="DDI-PubMed.25152400.s5.e3" text="xanthine" /><pair ddi="false" e1="DDI-PubMed.25152400.s5.e0" e2="DDI-PubMed.25152400.s5.e0" /><pair ddi="false" e1="DDI-PubMed.25152400.s5.e0" e2="DDI-PubMed.25152400.s5.e1" /><pair ddi="false" e1="DDI-PubMed.25152400.s5.e0" e2="DDI-PubMed.25152400.s5.e2" /><pair ddi="false" e1="DDI-PubMed.25152400.s5.e0" e2="DDI-PubMed.25152400.s5.e3" /><pair ddi="false" e1="DDI-PubMed.25152400.s5.e1" e2="DDI-PubMed.25152400.s5.e1" /><pair ddi="false" e1="DDI-PubMed.25152400.s5.e1" e2="DDI-PubMed.25152400.s5.e2" /><pair ddi="false" e1="DDI-PubMed.25152400.s5.e1" e2="DDI-PubMed.25152400.s5.e3" /><pair ddi="false" e1="DDI-PubMed.25152400.s5.e2" e2="DDI-PubMed.25152400.s5.e2" /><pair ddi="false" e1="DDI-PubMed.25152400.s5.e2" e2="DDI-PubMed.25152400.s5.e3" /></sentence><sentence text=" Immunoblot analysis quantified expression of XO and AMP-kinase (AMPK) in drug-treated human liver (HepG2) and primary kidney (HRCE) cells" /><sentence text=" In silico analysis identified miR-448 as a potential XO-regulator, whose expression level in HepG2 cells was examined by qPCR" /><sentence text=" Fluorimetric experiments revealed no direct interactions between XO and furosemide, nor did the combination of oxypurinol/furosemide alter the XO inhibition profile of oxypurinol"><entity charOffset="73-83" id="DDI-PubMed.25152400.s8.e0" text="furosemide" /><entity charOffset="112-122" id="DDI-PubMed.25152400.s8.e1" text="oxypurinol" /><entity charOffset="123-133" id="DDI-PubMed.25152400.s8.e2" text="furosemide" /><entity charOffset="169-179" id="DDI-PubMed.25152400.s8.e3" text="oxypurinol" /><pair ddi="false" e1="DDI-PubMed.25152400.s8.e0" e2="DDI-PubMed.25152400.s8.e0" /><pair ddi="false" e1="DDI-PubMed.25152400.s8.e0" e2="DDI-PubMed.25152400.s8.e1" /><pair ddi="false" e1="DDI-PubMed.25152400.s8.e0" e2="DDI-PubMed.25152400.s8.e2" /><pair ddi="false" e1="DDI-PubMed.25152400.s8.e0" e2="DDI-PubMed.25152400.s8.e3" /><pair ddi="false" e1="DDI-PubMed.25152400.s8.e1" e2="DDI-PubMed.25152400.s8.e1" /><pair ddi="false" e1="DDI-PubMed.25152400.s8.e1" e2="DDI-PubMed.25152400.s8.e2" /><pair ddi="false" e1="DDI-PubMed.25152400.s8.e1" e2="DDI-PubMed.25152400.s8.e3" /><pair ddi="false" e1="DDI-PubMed.25152400.s8.e2" e2="DDI-PubMed.25152400.s8.e2" /><pair ddi="false" e1="DDI-PubMed.25152400.s8.e2" e2="DDI-PubMed.25152400.s8.e3" /></sentence><sentence text=" In HepG2 cells, we found a significant decrease in XO protein expression following oxypurinol treatment, which was abolished after co-incubation with furosemide"><entity charOffset="84-94" id="DDI-PubMed.25152400.s9.e0" text="oxypurinol" /><entity charOffset="151-161" id="DDI-PubMed.25152400.s9.e1" text="furosemide" /><pair ddi="false" e1="DDI-PubMed.25152400.s9.e0" e2="DDI-PubMed.25152400.s9.e0" /><pair ddi="false" e1="DDI-PubMed.25152400.s9.e0" e2="DDI-PubMed.25152400.s9.e1" /></sentence><sentence text=" Probenecid alone or in combination with furosemide reduced XO protein expression significantly"><entity charOffset="41-51" id="DDI-PubMed.25152400.s10.e0" text="furosemide" /></sentence><sentence text=" qPCR analysis of miR-448 in HepG2 cells mirrored the drug-dependent changes in XO protein expression" /><sentence text=" In addition, oxypurinol and the combination of oxypurinol/furosemide significantly down-regulated AMPK protein expression in HRCE cells"><entity charOffset="14-24" id="DDI-PubMed.25152400.s12.e0" text="oxypurinol" /><entity charOffset="48-58" id="DDI-PubMed.25152400.s12.e1" text="oxypurinol" /><entity charOffset="59-69" id="DDI-PubMed.25152400.s12.e2" text="furosemide" /><pair ddi="false" e1="DDI-PubMed.25152400.s12.e0" e2="DDI-PubMed.25152400.s12.e0" /><pair ddi="false" e1="DDI-PubMed.25152400.s12.e0" e2="DDI-PubMed.25152400.s12.e1" /><pair ddi="false" e1="DDI-PubMed.25152400.s12.e0" e2="DDI-PubMed.25152400.s12.e2" /><pair ddi="false" e1="DDI-PubMed.25152400.s12.e1" e2="DDI-PubMed.25152400.s12.e1" /><pair ddi="false" e1="DDI-PubMed.25152400.s12.e1" e2="DDI-PubMed.25152400.s12.e2" /></sentence><sentence text=" In conclusion, we show for the first time that besides the established effects of allopurinol on the purine synthetic pathway the efficiency of allopurinol treatment of gout patients is based on two further complementary mechanisms, the direct inhibition of XO activity by the allopurinol metabolite oxypurinol and a down-regulation of XO protein expression"><entity charOffset="83-94" id="DDI-PubMed.25152400.s13.e0" text="allopurinol" /><entity charOffset="102-108" id="DDI-PubMed.25152400.s13.e1" text="purine" /><entity charOffset="145-156" id="DDI-PubMed.25152400.s13.e2" text="allopurinol" /><entity charOffset="278-289" id="DDI-PubMed.25152400.s13.e3" text="allopurinol" /><entity charOffset="301-311" id="DDI-PubMed.25152400.s13.e4" text="oxypurinol" /><pair ddi="false" e1="DDI-PubMed.25152400.s13.e0" e2="DDI-PubMed.25152400.s13.e0" /><pair ddi="false" e1="DDI-PubMed.25152400.s13.e0" e2="DDI-PubMed.25152400.s13.e1" /><pair ddi="false" e1="DDI-PubMed.25152400.s13.e0" e2="DDI-PubMed.25152400.s13.e2" /><pair ddi="false" e1="DDI-PubMed.25152400.s13.e0" e2="DDI-PubMed.25152400.s13.e3" /><pair ddi="false" e1="DDI-PubMed.25152400.s13.e0" e2="DDI-PubMed.25152400.s13.e4" /><pair ddi="false" e1="DDI-PubMed.25152400.s13.e1" e2="DDI-PubMed.25152400.s13.e1" /><pair ddi="false" e1="DDI-PubMed.25152400.s13.e1" e2="DDI-PubMed.25152400.s13.e2" /><pair ddi="false" e1="DDI-PubMed.25152400.s13.e1" e2="DDI-PubMed.25152400.s13.e3" /><pair ddi="false" e1="DDI-PubMed.25152400.s13.e1" e2="DDI-PubMed.25152400.s13.e4" /><pair ddi="false" e1="DDI-PubMed.25152400.s13.e2" e2="DDI-PubMed.25152400.s13.e2" /><pair ddi="false" e1="DDI-PubMed.25152400.s13.e2" e2="DDI-PubMed.25152400.s13.e3" /><pair ddi="false" e1="DDI-PubMed.25152400.s13.e2" e2="DDI-PubMed.25152400.s13.e4" /><pair ddi="false" e1="DDI-PubMed.25152400.s13.e3" e2="DDI-PubMed.25152400.s13.e3" /><pair ddi="false" e1="DDI-PubMed.25152400.s13.e3" e2="DDI-PubMed.25152400.s13.e4" /></sentence><sentence text=" The latter is compromised by addition of furosemide and might explain why patients receiving furosemide therapy require higher allopurinol doses"><entity charOffset="42-52" id="DDI-PubMed.25152400.s14.e0" text="furosemide" /><entity charOffset="94-104" id="DDI-PubMed.25152400.s14.e1" text="furosemide" /><entity charOffset="128-139" id="DDI-PubMed.25152400.s14.e2" text="allopurinol" /><pair ddi="false" e1="DDI-PubMed.25152400.s14.e0" e2="DDI-PubMed.25152400.s14.e0" /><pair ddi="false" e1="DDI-PubMed.25152400.s14.e0" e2="DDI-PubMed.25152400.s14.e1" /><pair ddi="false" e1="DDI-PubMed.25152400.s14.e0" e2="DDI-PubMed.25152400.s14.e2" /><pair ddi="false" e1="DDI-PubMed.25152400.s14.e1" e2="DDI-PubMed.25152400.s14.e1" /><pair ddi="false" e1="DDI-PubMed.25152400.s14.e1" e2="DDI-PubMed.25152400.s14.e2" /></sentence><sentence text=" miR-448 was identified as a potential drug-dependent XO regulator" /><sentence text=" Finally, down-regulation of AMPK protein expression in HRCE cells by administration of oxypurinol/furosemide reveals a possible new mechanism of renal drug-induced hyperuricemia"><entity charOffset="88-98" id="DDI-PubMed.25152400.s16.e0" text="oxypurinol" /><entity charOffset="99-109" id="DDI-PubMed.25152400.s16.e1" text="furosemide" /><pair ddi="false" e1="DDI-PubMed.25152400.s16.e0" e2="DDI-PubMed.25152400.s16.e0" /><pair ddi="false" e1="DDI-PubMed.25152400.s16.e0" e2="DDI-PubMed.25152400.s16.e1" /></sentence><sentence text="" /></document>